Announcement of Second Quarter Financial Results・The Medium-Term Management Plan

TSUMURA & CO.

Announcement of Second Quarter Financial Results・The Medium-Term Management Plan

Terukazu Kato
President,
Representative Director

• Previous
• Play from this slide
• Slide list
• Enlarge slide
• Next

Back

from the beginning

Second Quarter Business Results for Fiscal 2012

presenter :

Terukazu Kato
President, Representative Director

• 2Q Consolidated Performance for Fiscal 2012, ending March 31, 2013

• Key Points in 2Q Performance

• Top 10 Kampo Products by Sales Amount

• MR Activities (1): Sales Calls on Physicians

• MR Activities (2): Medical Institution Information Meetings

• MR Activities (3): Kampo Medicine Seminars

• Growth in Physicians Prescribing Kampo Medicine

• Analysis of 2Q Cost of Sales Ratio Compared with Last Fiscal Year

• Analysis of Inventories Increase

• Revision of FY2012 Full-Year Performance Forecasts

Medium-Term Management Plan(FY2012-2015)

Basic Policies

• Philosophy-Based Management

• Basic Philosophy

• Long-Term Business Vision "2021 Vision"

FY2012-2015 Medium-Term Management Plan

• Operating Environment: The Future of Medical Treatment in Japan

• Strengthening the Growth Base to Achieve Greater Value Creation

• Positioning of the New Medium-Term Management Plan

• Strategic Issues

• Reaching Cruising Speed for Boosting Growth and Corporate Value

• FY2015 (ending March 31, 2016) Performance Targets

Strategic Issue 1:Expanding the Kampo Medicine Market

• Expansion Strategy for Kampo Medicine Market

• Strategic Expansion in Use of Different Kampo Formulations

• Kampo Medicine Education System

• Double Blind Trials (DBT) of" Drug Fostering Program" Formulations

• Sales Forecast: Past Trends and Cumulative Growth in Formulations

Strategic Issue 1:Expanding the Kampo Medicine Market

Strategic Issue 2:Enhancing Earning Power

• Improvement in Profitability Scenario from a Medium-Term Perspective

• Reform of Cost Structure

• Measures to Reduce Manufacturing Cost

• Raising Productivity Through the Introduction of New Production Technology and Other Measures

• Stability of Crude Drug Prices

• Impact on Cost of Sales Ratio

• Selling, General and Administrative Expense (SG&A)

• Capital Investment to Achieve Sustained Growth

Strategic Issue 3:Executing Effective Financial and Capital Policies

• Financial and Capital Policies

• Human Resource Policy

• Environmental Resource Policy

@